Dr Sally Martin

Lecturer

School of Biomedicine

Faculty of Health and Medical Sciences

Dr Martin is a teaching-focussed academic in the School of Biomedicine, University of Adelaide. She is currently the course coordinator of Human Anatomy and Physiology 1A (ANAT SC 1102) and Human Anatomy and Physiology 1B (ANAT SC 1103), and also teaches into Create.Communicate.Connect (HLTH SC 1002) and Foundations of Medicine (MEDIC ST 1501). Dr Martin is an Education Specialist and is a member of the Adelaide Education Academy, and sits on the BHMS Learning & Teaching Committee (Academic Lead, First Year Student Experience), the BHMS Academic Review Committee (ARC), and the School of Biomedicine Course Monitoring and Evaluation committee.

Dr Martin completed her PhD on bone marrow angiogenesis and osteolytic bone disease in the haematological malignancy, multiple myeloma in 2009. Following the completion of her PhD, Dr Martin worked as a post-doctoral research at the Institute of Medical and Veterinary Science, SA Pathology, and SAHMRI, examining the role of the PI3K and mTOR signalling pathways in bone development, and how these pathways could be exploited to stimulate bone formation in disease settings such as osteoporosis and tumour-associated bone loss. Her more recent projects included investigating (1) the role of the mTOR signalling pathways in mesenchymal stem cell biology, (2) the role of the mTOR signalling pathways in regulating skeletal biology and bone remodelling, and (3) the role of skeletal mTORC1 signalling in B-cell development and glucose homeostasis.

Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Appointments

Date	Position	Institution name
2019 - ongoing	Lecturer, Course Coordinator	University of Adelaide
2015 - 2019	Post-doctoral Researcher	University of Adelaide, Adelaide
2012 - 2019	Affiliate Lecturer	University of Adelaide
2009 - 2015	Post-doctoral Researcher	SA Pathology
2003 - 2008	Technical Assistant (part-time)	Institute of Medical and Veterinary Science (IMVS)

Education

Date	Institution name	Country	Title
2005 - 2008	University of Adelaide, Adelaide	Australia	PhD
2000 - 2004	University of South Australia	Australia	Bachelor of Medical and Pharmaceutical Biotechnology (Hons)

Journals

Year	Citation
2021	Tangseefa, P., Martin, S. K., Chin, P. Y., Breen, J., Mah, C. Y., Baldock, P. A., . . . Zannettino, A. C. W. (2021). The mTORC1 complex in pre-osteoblasts regulates whole-body energy metabolism independently of osteocalcin. Bone Research, 9(1), 10-1-10-17. DOI Scopus3 WoS3 Europe PMC4
2021	Tangseefa, P., Martin, S. K., Arthur, A., Panagopoulos, V., Page, A. J., Wittert, G. A., . . . Zannettino, A. C. W. (2021). Deletion of Rptor in preosteoblasts reveals a role for the mammalian target of rapamycin complex 1 (mTORC1) complex in dietary-induced changes to bone mass and glucose homeostasis in female mice. JBMR Plus, 5(5), 1-14. DOI Scopus1 WoS1
2020	Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., . . . Proud, C. G. (2020). Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.. Cellular and molecular life sciences : CMLS, 78(1), 249-270. DOI Scopus14 WoS13 Europe PMC8
2018	Martin, S., Fitter, S., El Khawanky, N., Grose, R., Walkley, C., Purton, L., . . . Zannettino, A. (2018). mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis. Scientific Reports, 8(1), 14501-1-14501-10. DOI Scopus16 WoS14 Europe PMC13
2018	Tangseefa, P., Martin, S., Fitter, S., Baldock, P., Proud, C., & Zannettino, A. (2018). Osteocalcin-dependent regulation of glucose metabolism and fertility: skeletal implications for the development of insulin resistance. Journal of Cellular Physiology, 233(5), 3769-3783. DOI Scopus18 WoS13 Europe PMC10
2017	Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463. DOI Scopus43 WoS37 Europe PMC32
2017	Fitter, S., Matthews, M., Martin, S., Xie, J., Ooi, S., Walkley, C., . . . Zannettino, A. (2017). mTORC1 plays an important role in skeletal development by controlling preosteoblast differentiation. Molecular and Cellular Biology, 37(7), e00668-1-e00668-20. DOI Scopus52 WoS44 Europe PMC40
2015	Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354. DOI Scopus32 WoS28 Europe PMC23
2015	Martin, S., Fitter, S., Dutta, A., Matthews, M., Walkley, C., Hall, M., . . . Zannettino, A. (2015). Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells, 33(4), 1359-1365. DOI Scopus79 WoS70 Europe PMC65
2015	Martin, S., Gan, Z., Fitter, S., To, L., & Zannettino, A. (2015). The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 39(3), 380-387. DOI Scopus20 WoS18 Europe PMC14
2015	Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38. DOI Scopus26 WoS26 Europe PMC24
2015	Forristal, C. E., Brown, A. L., Helwani, F. M., Winkler, I. G., Nowlan, B., Barbier, V., . . . Levesque, J. P. (2015). Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 29(10), 2075-2085. DOI Scopus31 WoS27 Europe PMC31
2011	Martin, S., Diamond, P., Gronthos, S., Peet, D., & Zannettino, A. (2011). The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 25(10), 1533-1542. DOI Scopus107 WoS93 Europe PMC85
2010	Martin, S., Fitter, S., Bong, L., Drew, J., Gronthos, S., Shepherd, P., & Zannettino, A. (2010). NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of Bone and Mineral Research, 25(10), 2126-2137. DOI Scopus53 WoS51 Europe PMC43
2010	Williams, S., Martin, S., Vincent, C., Gronthos, S., Zheng, T., Atkins, G., & Zannettino, A. (2010). Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 150(3), 373-376. DOI Scopus6 WoS6 Europe PMC3
2010	Martin, S., Diamond, P., Williams, S., To, L., Peet, D., Fujii, N., . . . Zannettino, A. (2010). Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 95(5), 776-784. DOI Scopus82 WoS73 Europe PMC56
2010	Psaltis, P., Paton, S., See, F., Arthur, A., Martin, S., Itescu, S., . . . Zannettino, A. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Journal of Cellular Physiology, 223(2), 530-540. DOI Scopus128 WoS115 Europe PMC92
2009	Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2009). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. Journal of Bone and Mineral Research, 24(7), 1150-1161. DOI Scopus60 WoS61 Europe PMC45
2009	Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009. DOI Scopus32 WoS30 Europe PMC27
2006	Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2006). Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma. Clinical Cancer Research, 12(23), 6973-6977. DOI Scopus33 WoS30 Europe PMC21
2005	Zannettino, A., Farrugia, A., Kortesidis, A., Manavis, J., To, L., Martin, S., . . . Gronthos, S. (2005). Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Research, 65(5), 1700-1709. DOI Scopus180 WoS165 Europe PMC122
2004	Martin, S., To, L., Horvath, N., & Zannettino, A. (2004). Angiogenesis in multiple myeloma: Implications in myeloma therapy. Cancer Reviews: Asia-Pacific, 2(2), 119-129. DOI

Book Chapters

Year	Citation
2008	Zannettino, A., Martin, S. K., Gronthos, S., To, L., & Peet, D. (2008). The role of CXCL12 in multiple myeloma. In F. columbus (Ed.), Cancer Research Progress. Nova Science Publishers.

Conference Papers

Year	Citation
2018	Tangseefa, P., Martin, S. K., Wilczek, V., Baldock, P., Proud, C. G., Fitter, S., & Zannettino, A. C. W. (2018). Metabolic and reproductive abnormalities in mice with impaired skeletal-mTORC1 function mirror a dietary restriction phenotype. In CLINICAL ENDOCRINOLOGY Vol. 89 (pp. 19). Perth, AUSTRALIA: WILEY.
2017	Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2013	Forristal, C. E., Helwani, F., Martin, S., Nowlan, B., Winkler, I. G., Zannettino, A., & Levesque, J. -P. (2013). Hypoxia Inducible Factor (HIF)-2α Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS1
2008	Martin, S. K., Diamond, P., To, L. B., Pect, D., Gronthos, S., & Zannettino, A. W. W. (2008). CXCL12 Expression Is Regulated by HIF-2a in Multiple Myeloma Plasma Cells. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES.
2008	Diamond, P., Labrinidis, A., Martin, S. K., Farrugia, A., Gronthos, S., To, L. B., . . . Zannettino, A. (2008). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In Journal of Bone and Mineral Research Vol. 23 (pp. S262). Montreal: American Society for Bone and Mineral Research.
2007	Martin, S. K., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L. B., & Zannettino, A. (2007). Tumour angiogenesis is associated with plasma levels of stromal-derived factor-1a in patients with multiple myeloma. In Haematologica Vol. 92 (pp. 125-126). Kos, Greece: Ferrata Storti Foundation.
2007	Martin, S. K., Dewar, A. L., Farrugia, A. N., Horvath, N., Gronthos, S., To, L. B., & Zannettino, A. C. W. (2007). Tumour angiogenesis correlates with plasma levels of CXCL12 in patients with multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 125-126). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.
2007	Diamond, P., Labrinidis, A., Martin, S. K., Farrugia, A. N., Gronthos, S., To, L. B., . . . Zannettino, A. C. W. (2007). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 130). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.

Conference Items

Year	Citation
2013	Forristal, C., Helwani, F., Nowlan, B., Martin, S., Zannetino, A., & Levesque, J. -P. (2013). HYPOXIA INDUCIBLE FACTOR (HIF)-2 alpha ENHANCES PROLIFERATION OF MALIGNANT HAEMATOPOIETIC CELLS IN THE HYPOXIC MALIGNANT BONE MARROW. Poster session presented at the meeting of EXPERIMENTAL HEMATOLOGY. Vienna, AUSTRIA: ELSEVIER SCIENCE INC. DOI

Diabetes Australia grant (2020), Investigating the mechanisms by which bone-specific mTORC1 inhibition protects mice against diet-induced insulin resistance” AUD $60,000.

University of Adelaide ECR Mentored Project Development Grant (2018), The role of bone-derived secretagogues in men with Type 2 diabetes” AUD $13,179.

Mary Overton Early Career Research Fellowship (2012 - 2015), The role of the raptor and rictor signalling pathways in skeletal biology, AUD$252,000

Centre for Stem Cell Research Project Grant 2012, The role of raptor and rictor in MSC differentiation, AUD$75,000

Novartis Pharmaceuticals Project Grant 2011, Can the dual PI3K/mTOR inhibitor NVP-BEZ235 be used to stimulate bone formation in multiple myeloma? AUD$75,000.

Human Anatomy and Physiology 1A (ANAT SC 1102)

Human Anatomy and Physiology 1B (ANAT SC 1103)

Create. Communicate. Connect (HLTH SC 1002)

Foundations of Medicine (MEDIC ST 1501)

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2017 - 2020	Co-Supervisor	The Role of Osteoblast-mTORC1 in the Regulation of Glucose Metabolism	Doctor of Philosophy	Doctorate	Full Time	Miss Pawanrat Tangseefa
2013 - 2018	Co-Supervisor	The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development	Doctor of Philosophy	Doctorate	Part Time	Ms Mary Patricia Matthews

Board Memberships

Date	Role	Board name	Institution name	Country
2021 - ongoing	Board Member	BHMS Program Learning & Teaching Committee	University of Adelaide	Australia
2019 - 2020	Member	Allied Health Programs Board	University of Adelaide	Australia

Committee Memberships

Date	Role	Committee	Institution	Country
2021 - ongoing	Member	BHMS Academic Review Committee	University of Adelaide	Australia
2021 - ongoing	Member	School of Biomedicine Course Monitoring and Evaluation Committee	University of Adelaide	Australia

Memberships

Date	Role	Membership	Country
2024 - ongoing	Member	HERDSA	Australia
2023 - ongoing	Member	Adelaide Education Academy	Australia
2022 - ongoing	Member	Women’s Professional Development Network	Australia

Position: Lecturer
Email: sally.martin@adelaide.edu.au
Campus: North Terrace
Building: Helen Mayo North, floor 2
Org Unit: Medical Sciences